Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5552554 | Biomedicine & Pharmacotherapy | 2017 | 7 Pages |
AimThe aim of this study is to explain effect and mechanism of Sophoridine to suppress Hepatocellular carcinoma in vitro and vivo.MethodsIn vitro experiment, the HepG2 cells were divided into 5 groups: 0 μg/mL Sophoridine treated group (0âμg/mL group); 10 μg/mL matrine treated group (10 μg/mL group); 20 μg/mL matrine treated group (20 μg/mL group) and 10 μg/mL Paclitaxel treated group (Positive drug group). Measuring the cell proliferation of difference groups by MTS assay; evaluating cell apoptosis of difference by flow cytometry; the cell invasion and migration abilities of difference HepG2 cells were measured by transwell and wound healing testing; measuring the relative proteins expression in difference groups. In vovo experiment, the nude mice were divided into 5 groups: 0 μg/mL, 5 μg/mL, 10 μg/mL, 20 μg/mL and Positive drug groups, after executing, taking the tumor tissue from nude mice of difference groups, measuring the tumor volume and weight; evaluating the PTEN protein expression in tumor tissue by Immunohistochemistry (IHC).ResultsIn the cell experiments, Compared with 0 μg/mL group, cell proliferation rates were significantly reduced, cell aopotosis were significantly increased and invasion and wound healing abilities were significantly decreased in marine treated groups with dose-dependent (P < 0.05, respectively). In the nude mice experiment, the tumor volume and weight of matrine treated groups were significantly decreased compared with 0âμg/mL group with dose-dependent (P < 0.05, respectively). And the PTEN protein expression of Sophoridine treated groups were significantly decreased compared with 0 μg/mL group with dose-dependent (P < 0.05, respectively).ConclusionSophoridine had anti-cance effects to suppress HepG2 activities by regulation PTEN/PI3K/AKT, Caspase-3/-9 and MMP-2/-9 signaling pathway.